Welcome to our dedicated page for Cryoport SEC filings (Ticker: CYRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Need to know how Cryoport’s cryogenic logistics deals with FDA requirements, capital spending, or new biotech partnerships? Each document is packed with technical details that make traditional dry ice look simple. That complexity is exactly why investors search for “Cryoport SEC filings explained simply”.
Stock Titan solves the problem. Our AI reads every Cryoport annual report 10-K simplified, parses each Cryoport quarterly earnings report 10-Q filing, and flags Cryoport 8-K material events explained in minutes. Want to track management confidence? Receive real-time alerts on Cryoport Form 4 insider transactions real-time, including every Cryoport executive stock transactions Form 4.
Here’s what you can do in one place:
- Compare liquid-nitrogen shipper revenue lines across quarters using our Cryoport earnings report filing analysis.
- Monitor Cryoport insider trading Form 4 transactions before key trial milestones are announced.
- Review governance details inside the Cryoport proxy statement executive compensation without combing through appendices.
- Save hours by understanding Cryoport SEC documents with AI summaries that translate complex supply-chain disclosures into plain language.
Whether you’re modeling future demand for cell & gene therapy logistics or checking covenant compliance, you’ll find comprehensive coverage of 10-K, 10-Q, 8-K, S-1, and ownership filings—updated the moment they hit EDGAR. Make faster, well-informed decisions with unbiased AI insight on every Cryoport filing.
CryoPort insider exercise and share ownership update. Jerrell Shelton, President and CEO and a director of CryoPort, exercised options on 08/13/2025 to acquire 25,000 shares of common stock at an exercise price of $5. After this cash exercise, Shelton beneficially owns 1,062,419 shares. The option grant referenced vests monthly over 48 months beginning 08/19/2015; the exercised options were part of that schedule. The filing indicates the exercise was a cash exercise and there was no immediate sale of the underlying shares.
Alger Associates, Inc. filed an amendment to Schedule 13G reporting beneficial ownership of 2,358,940 shares of CryoPort, Inc. common stock, representing 4.7% of the outstanding class. The filing states Alger Associates has sole voting and sole dispositive power over these shares and that the securities are held in the ordinary course of business, not for the purpose of changing or influencing control. The filing identifies Fred Alger Management, LLC and Alger Group Holdings as related entities that manage accounts holding the securities.
Brown Capital Management, LLC filed an amended Schedule 13G reporting beneficial ownership of 3,798,962 shares of CryoPort Inc. common stock, representing 7.58% of the class. The filing states Brown Capital has sole voting power over 1,529,549 shares and sole dispositive power over all 3,798,962 shares. The shares are held by various investment advisory clients of Brown Capital, which the firm says gives it beneficial ownership under Rule 13d-3 because of its discretionary authority to direct investment and voting decisions. The filing includes a certification that the holdings are held in the ordinary course of business and are not intended to influence control of the issuer.
Cryoport completed the divestiture of its CryoPDP specialty courier business to DHL for $133.0 million, which included repayment of approximately $77.2 million of intercompany loans and generated a reported $116,662 thousand gain on disposal classified as discontinued operations. Proceeds from the divested business of $210,239 thousand were reflected in investing cash flows and materially increased the Company's liquidity.
Total revenue increased to $45,454 thousand for the three months ended June 30, 2025 (up from $39,709) and to $86,494 thousand for the six months (up from $77,000). Results from continuing operations remained a loss: $(12,014) thousand for the quarter and $(18,752) thousand for the six months, while net income including discontinued operations was $105,180 thousand and $93,199 thousand, respectively. Cash and cash equivalents rose to $243,416 thousand at June 30, 2025; total assets were $773,927 thousand and total stockholders' equity was $515,391 thousand. Convertible senior notes noncurrent balance was $184,504 thousand and accumulated impairment losses related to goodwill/intangibles totaled $104,132 thousand.
On 08/04/2025 Cryoport (CYRX) filed a Form 4 showing that President & CEO Jerrell Shelton exercised 25,000 stock options at an exercise price of $5 on 07/31/2025. This was a cash exercise with no subsequent sale of the underlying shares. As a result, Shelton’s direct holdings rose to 1,037,419 common shares.
The option was originally granted on 08/20/2015 and vested in equal monthly installments over 48 months; the filing confirms the award is now fully exercised and retired. The transaction modestly increases insider ownership and may indicate management confidence, but represents only about 2.4 % of Shelton’s total stake and does not involve open-market buying. No additional financial metrics, earnings data, or strategic commentary were included in the filing.
FAQ
What is the current stock price of Cryoport (CYRX)?
What is the market cap of Cryoport (CYRX)?
